Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) SVP Sells 918 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 918 shares of Twist Bioscience stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $37,555.38. Following the transaction, the senior vice president now directly owns 130,912 shares in the company, valued at $5,355,609.92. The trade was a 0.70 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Paula Green also recently made the following trade(s):

• On Monday, February 3rd, Paula Green sold 1,259 shares of Twist Bioscience stock. The stock was sold at an average price of $49.35, for a total transaction of $62,131.65.
• On Friday, January 3rd, Paula Green sold 160 shares of Twist Bioscience stock. The shares were sold at an average price of $45.59, for a total value of $7,294.40.
• On Friday, December 20th, Paula Green sold 282 shares of Twist Bioscience stock. The shares were sold at an average price of $44.90, for a total value of $12,661.80.

Twist Bioscience Stock Performance

TWST stock traded down $2.72 during trading hours on Monday, hitting $36.71. 1,733,358 shares of the stock were exchanged, compared to its average volume of 982,978. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. The company has a 50-day simple moving average of $46.54 and a two-hundred day simple moving average of $45.47. The firm has a market capitalization of $2.19 billion, a P/E ratio of -10.86 and a beta of 2.15.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm’s quarterly revenue was up 24.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.75) earnings per share. On average, analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently bought and sold shares of the company. Farther Finance Advisors LLC lifted its holdings in shares of Twist Bioscience by 1,173.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 3,401 shares of the company’s stock worth $154,000 after acquiring an additional 3,134 shares during the period. Principal Financial Group Inc. boosted its position in Twist Bioscience by 67.5% in the third quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock valued at $9,301,000 after buying an additional 82,953 shares in the last quarter. Privium Fund Management B.V. increased its holdings in Twist Bioscience by 53.4% in the 3rd quarter. Privium Fund Management B.V. now owns 6,950 shares of the company’s stock worth $314,000 after purchasing an additional 2,420 shares in the last quarter. Los Angeles Capital Management LLC raised its position in Twist Bioscience by 18.3% in the third quarter. Los Angeles Capital Management LLC now owns 12,192 shares of the company’s stock valued at $551,000 after purchasing an additional 1,888 shares during the last quarter. Finally, Aigen Investment Management LP grew its holdings in shares of Twist Bioscience by 84.0% during the third quarter. Aigen Investment Management LP now owns 9,037 shares of the company’s stock worth $408,000 after purchasing an additional 4,125 shares during the last quarter.

Analyst Ratings Changes

Several brokerages have commented on TWST. Barclays set a $58.00 price target on shares of Twist Bioscience and gave the stock an “overweight” rating in a research report on Monday, February 3rd. TD Cowen reissued a “buy” rating and set a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. Wolfe Research assumed coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective on the stock. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Finally, Robert W. Baird lifted their price target on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average target price of $54.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.